Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Assets (2023 - 2025)

Kura Oncology (KURA) has disclosed Non-Current Assets for 3 consecutive years, with $29.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 93.74% to $29.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $100.3 million through Dec 2025, up 60.79% year-over-year, with the annual reading at $29.7 million for FY2025, 93.74% up from the prior year.
  • Non-Current Assets for Q4 2025 was $29.7 million at Kura Oncology, up from $28.7 million in the prior quarter.
  • The five-year high for Non-Current Assets was $29.7 million in Q4 2025, with the low at $9.1 million in Q2 2023.
  • Average Non-Current Assets over 3 years is $17.6 million, with a median of $15.9 million recorded in 2024.
  • The sharpest move saw Non-Current Assets dropped 6.83% in 2024, then skyrocketed 93.74% in 2025.
  • Over 3 years, Non-Current Assets stood at $16.5 million in 2023, then dropped by 6.83% to $15.3 million in 2024, then surged by 93.74% to $29.7 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $29.7 million, $28.7 million, and $22.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.